Long-Term Follow-Up of MonumenTAL-1

Opinion
Video

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

Video content above is prompted by the following:

  • Please discuss the efficacy data, focusing on PFS and DOR, presented at EHA 2024 on the long-term follow-up results of the phase 1/2 MonumenTAL-1 study of talquetamab in patients with RRMM.
    • What factors might contribute to the longer DOR with Q2W dosing compared to QW dosing in patients naive to prior TCR?
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Related Content
Investigators are currently assessing the antibody drug conjugate HDP-101 as part of a phase 1/2a study.

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

Russ Conroy
October 23rd 2025
Article

Investigators are currently assessing the antibody drug conjugate HDP-101 as part of a phase 1/2a study.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma

Russ Conroy
October 16th 2025
Article

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The most common any-grade AE was diarrhea, occurring in 74.0% of the experimental group and 72.2% of the standard group.

Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma

Tim Cortese
October 6th 2025
Article

Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.

In the analysis comparing D-VRd with other regimens for MRD-negative CR rate, there was an 81% probability that it was favorable vs Isa-VRd.

Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

Tim Cortese
October 1st 2025
Article

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.